Abstract:Amyloid-β (Aβ) accumulation in Alzheimer disease (AD) is typically measured using SUV ratio and the centiloid (CL) scale. The low spatial resolution of PET images is known to degrade quantitative metrics because of the partial-volume effect. This article examines the impact of spatial resolution, as determined by the reconstruction configuration, on the Aβ PET quantitation in both cross-sectional and longitudinal data. Methods: The cross-sectional study involved 89 subjects with 20-min [18F]florbetapir scans generated on an mCT (44 Aβ-negative [Aβ-], 45 Aβ-positive [Aβ+]) using 69 reconstruction configurations, which varied in number of iteration updates, point-spread function, time-of-flight, and postreconstruction smoothing. The subjects were classified as Aβ- or Aβ+ visually. For each reconstruction, Aβ CL was calculated using CapAIBL, and the spatial resolution was calculated as full width at half maximum (FWHM) using the barrel phantom method. The change in CLs and the effect size of the difference in CLs between Aβ- and Aβ+ groups with FWHM were examined. The longitudinal study involved 79 subjects (46 Aβ-, 33 Aβ+) with three 20-min [18F]flutemetamol scans generated on an mCT. The subjects were classified as Aβ- or Aβ+ using a cutoff CL of 20. All scans were reconstructed using low-, medium-, and high-resolution configurations, and Aβ CLs were calculated using CapAIBL. Since linear Aβ accumulation was assumed over a 10-y interval, for each reconstruction configuration, Aβ accumulation rate differences (ARDs) between the second and first periods were calculated for all subjects. Zero ARD was used as a consistency metric. The number of Aβ accumulators was also used to compare the sensitivity of CL across reconstruction configurations. Results: In the cross-sectional study, CLs in both the Aβ- and the Aβ+ groups were impacted by the FWHM of the reconstruction method. Without postreconstruction smoothing, Aβ- CLs increased for a FWHM of 4.5 mm or more, whereas Aβ+ CLs decreased across the FWHM range. High-resolution reconstructions provided the best statistical separation between groups. In the longitudinal study, the median ARD of low-resolution reconstructed data for the Aβ- group was greater than zero whereas the ARDs of higher-resolution reconstructions were not significantly different from zero, indicating more consistent rate estimates in the higher-resolution reconstructions. Higher-resolution reconstructions identified 10 additional Aβ accumulators in the Aβ- group, resulting in a 22% increased group size compared with the low-resolution reconstructions. Higher-resolution reconstructions reduced the average CLs of the negative group by 12 points. Conclusion: High-resolution PET reconstructions, inherently less impacted by partial-volume effect, may improve Aβ PET quantitation in both cross-sectional and longitudinal data. In the cross-sectional analysis, separation of CLs between Aβ- and Aβ+ cohorts increased with spatial resolution. Higher-resolution reconstructions also exhibited both improved consistency and improved sensitivity in measures of Aβ accumulation. These features suggest that higher-resolution reconstructions may be advantageous in early-stage AD therapies.

Impact of amyloid PET in the clinical care of veterans in a tertiary memory disorders clinic

[P2-396]: HOW AMYLOID PET CHANGES COGNITIVE CARE: A BROADER VIEW

Elevated Amyloid-β PET Scan and Cognitive and Functional Decline in Mild Cognitive Impairment and Dementia of Uncertain Etiology

[IC‐P‐007]: HOW AMYLOID PET CHANGES COGNITIVE CARE: A BROADER VIEW

Incremental value of amyloid PET in a tertiary memory clinic setting in China

Added value and limitations of amyloid-PET imaging: review and analysis of selected cases of mild cognitive impairment and dementia.

Psychosocial implications of learning amyloid PET results in an observational cohort

Clinical, Neuropsychological, and Neuroimaging Characteristics of Amyloid- Positive Vs. Amyloid-negative Patients with Clinically Diagnosed Alzheimer’s Disease and Amnestic Mild Cognitive Impairment

The Who, When, Why, and How of PET Amyloid Imaging in Management of Alzheimer’s Disease—Review of Literature and Interesting Images

Amyloid PET in Dementia Syndromes: A Chinese Multicenter Study

International Nuclear Medicine Consensus on the Clinical Use of Amyloid Positron Emission Tomography in Alzheimer’s Disease

The Use of Event Related Potentials to Predict Amyloid PET Status Among Patients from a Memory Disorders Clinic

Amyloid‐β PET in Alzheimer's Disease: A Systematic Review and Bayesian Meta‐analysis

Using Positron Emission Tomography And Florbetapir F 18 To Image Cortical Amyloid In Patients With Mild Cognitive Impairment Or Dementia Due To Alzheimer Disease

A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment

Neuropsychiatric Profiles and Cerebral Amyloid Burden in Adults without Dementia

P1‐007: Discrepant Diagnostic Classification with AV45‐PET and FDG‐PET of Clinically Diagnosed Alzheimer's Patients in the Alzheimer's Disease Neuroimaging Initiative

PET/CT/MRI in Clinical Trials of Alzheimer's Disease

Impact of PET Reconstruction on Amyloid-β Quantitation in Cross-Sectional and Longitudinal Analyses

Discrepant diagnostic classification with AV45-PET and FDG-PET of clinically diagnosed Alzheimer's patients in the Alzheimer's Disease Neuroimaging Initiative

Computerized decision support is an effective approach to select memory clinic patients for amyloid-PET